Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

OBJECTIVE: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. MATERIALS & METHODS: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). RESULTS: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. CONCLUSION: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.